Phase III ARANOTE Trial of Darolutamide & ADT Redu...
Category : Clinical Trial Update 18 September 2024Phase III ARANOTE trial of darolutamide plus ADT significantly reduced the risk of radiological prog...
Phase III ARANOTE trial of darolutamide plus ADT significantly reduced the risk of radiological prog...
Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF...
Aura Biosciences announces positive results from phase 2 end of study of bel-sar as a first-line tre...
VYNE Therapeutics reports positive phase 1a SAD data for VYN202, a novel BD2-selective BET inhibitor...
Merck reports positive top-line results from phase 3 trial evaluating efficacy and safety of Gardasi...